Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Australian clinical practice guideline: diagnosis and treatment of idiopathic multicentric Castleman disease.

Internal medicine journal·2026

Same author

A Case of Primary Cutaneous BRAF<sup>V600E+</sup> Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA.

The Australasian journal of dermatology·2026

Same author

On the RAdR in relapsed T-cell lymphoma.

Blood advances·2026

Same author

Clinical outcomes of mature T- and NK-cell lymphomas in hepatitis B virus positive individuals: results from the PETAL Global Consortium.

Leukemia & lymphoma·2026

Same author

Brentuximab vedotin and nivolumab in combination with chemotherapy for nonbulky, early-stage classical Hodgkin lymphoma.

Blood·2025

Same author

Relapsed/refractory mycosis fungoides and Sezary syndrome: biology, clinical manifestations and therapeutic options.

Leukemia & lymphoma·2025

Search research articles

Related Experiment Video

Updated: Nov 3, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Targeted Approaches to T-Cell Lymphoma.

Sean Harrop¹, Chathuri Abeyakoon², Carrie Van Der Weyden¹

¹Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia.

Journal of Personalized Medicine

|June 2, 2021

Summary

Targeted therapies are advancing treatment for rare T-cell lymphomas, offering new hope beyond current options. This review details novel antibody, small molecule, and immune-based treatments for Peripheral T-cell lymphomas and Cutaneous T-cell lymphomas.

Keywords:

immunotherapy monoclonal antibodies novel agents

More Related Videos

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Related Experiment Videos

Last Updated: Nov 3, 2025

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Non-Viral Engineering of Primary Human T Cells via Homology-Mediated End-Joining Targeted Integration of Large DNA Templates

Published on: May 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

Area of Science:

Hematology
Oncology
Immunology

Background:

T-cell lymphomas are rare Non-Hodgkin's lymphomas originating from mature T-lymphocytes.
These lymphomas are categorized into Peripheral T-cell lymphomas and Cutaneous T-cell lymphomas.
Current treatment outcomes for T-cell lymphomas are generally unsatisfactory.

Purpose of the Study:

To provide an up-to-date overview of targeted therapies for T-cell lymphomas.
To highlight advancements in treatment strategies for these rare cancers.

Main Methods:

Review of current literature on T-cell lymphogenesis and therapeutic targets.
Analysis of novel antibody-based treatments.
Evaluation of small molecule inhibitors and immune-based therapies.

Main Results:

Understanding of T-cell lymphogenesis has identified new therapeutic targets.
A rapid expansion of treatment options for T-cell lymphomas is occurring.
Novel therapeutic approaches include antibody-based treatments, small molecule inhibitors, and immune-based therapies.

Conclusions:

Targeted therapies represent a significant advancement in managing T-cell lymphomas.
New treatments offer improved prospects for patients with Peripheral T-cell lymphomas and Cutaneous T-cell lymphomas.
Further research into targeted therapies is crucial for optimizing clinical outcomes.